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The association between adherence to anti-diabetes medicine, the 1 
measurement of this adherence, and HbA1c 2 
 3 
Abstract 4 
Background: Adherence to medicines is important in subjects with diabetes, as 5 
nonadherence is associated with an increased risk of morbidity and mortality.  However, it is 6 
not clear whether there is an association between adherence to medicines and glycaemic 7 
control, as not all studies have shown this. One of the reasons for this discrepancy may be 8 
that, although there is a standard measure of glycaemic control i.e. HbA1c, there is no 9 
standard measure of adherence to medicines.  Adherence to medicines can be measured 10 
either qualitatively by Morisky or non-Morisky methods or quantitatively using the medicines 11 
possession ratio (MPR).   12 
Aims of the review:  The aims of this literature review are (i) to determine whether there is an 13 
association between adherence to anti-diabetes medicines and glycaemic control, and (ii) 14 
whether any such association is dependent on how adherence is measured.   15 
Methods: A literature search of Medline, CINAHL and the Internet (Google) was undertaken 16 
with search terms; ‘diabetes’ with ‘adherence’ (or compliance, concordance, persistence, 17 
continuation) with ‘HbA1c’ (or glycaemic control).    18 
Results: Twenty-three studies were included; 10 qualitative and 12 quantitative studies, and 19 
one study using both methods.  For the qualitative methods measurements of adherence to 20 
anti-diabetes medicines (non-Morisky and Morisky), eight out of ten studies show an 21 
association with HbA1c.  Nine of 10 studies using the quantitative MPR, and two studies 22 
using MPR for insulin only, have also shown an association between adherence to anti-23 
diabetes medicines and HbA1c.  However, the one study that used both Morisky and MPR 24 
did not show an association.  Three of the four studies that did not show a relationship, did 25 
not use a range of HbA1c values in their regression analysis.  The other study that did not 26 
show a relationship was specifically in a low income population. 27 
Conclusions: Most studies show an association between adherence to anti-diabetes 28 
medicines and HbA1c levels, and this seems to be independent of method used to measure 29 
adherence.  However, to show an association it is necessary to have a range of HbA1c 30 
values.  Also, the association is not always apparent in low income populations.31 
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 34 
Impact of findings on practice 35 
• In practice, high HbA1c levels in subjects prescribed medicines for type 2 diabetes 36 
are considered suggestive of poor adherence to medicines 37 
• An association between poor adherence to medicines and high HbA1c levels is 38 
assumed, but has not been clearly shown 39 
• This review shows that most studies do show an association between adherence to 40 
anti-diabetes medicines and HbA1c levels such that poor adherence is associated 41 
with high HbA1c levels, and that this is irrespective of method for measuring 42 
adherence 43 
• In practice, when subjects with type 2 diabetes have high HbA1c levels, adherence to 44 
anti-diabetes medicines should be considered, and subjects should be counselled to 45 
adhere to their anti-diabetes medicines. 46 
  47 
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Introduction 48 
There is a significant relationship between glycaemia (HbA1c levels) and clinical 49 
complications with the higher the levels, the greater the complications [1,2].  There are many 50 
factors that influence glycaemic control, including older age, higher education level, higher 51 
patient activation, lower diabetes-related emotional distress, better diet and exercise 52 
behaviours, low body mass index (BMI), shorter duration of disease, and knowledge of 53 
HbA1c targets, which have all been shown by multiple linear regression to be associated 54 
with good glycaemic control [3].  In addition, adherence to medicines may be associated with 55 
glycaemic control. 56 
In subjects with diabetes, adherence to medicines is important, as nonadherence is 57 
associated with an increased risk of morbidity and mortality.  Nonadherence to insulin in 58 
adolescents with type 1 diabetes is associated with hospital admissions for acute diabetes 59 
complications e.g. diabetic ketoacidosis [4].  In subjects with type 2 diabetes, nonadherence 60 
to medicines is associated with increased risk of comorbidity severity, emergency room visits 61 
[5], and hospitalization [6,7], increased total annual health care costs [5,8], and increased 62 
risk for all-cause mortality [7]. 63 
However, although adherence to anti-diabetes medicines is a factor affecting HbA1c levels, 64 
not all studies have shown that adherence is associated with HbA1c [9,10,11,12].  One of 65 
the reasons for this discrepancy may be that, although there is a standard measure of 66 
glycaemic control i.e. HbA1c, there is no standard measure of adherence to medicines.  The 67 
aims of this literature review are (i) to determine whether there is an association between 68 
adherence to anti-diabetes medicines and glycaemic control, and (ii) whether any such 69 
association is dependent on how adherence is measured.  Thus, in this review, we consider 70 
any association between adherence to medicines measured qualitatively or quantitatively 71 
and HbA1c levels.   72 
The qualitative methods used to measure adherence to medicines initially were variable, and 73 
this made it difficult to compare papers on adherence to medicines.  Partly, to make it easier 74 
to compare studies on adherence to medicine, the Morisky scale was introduced (Table 1). 75 
The Morisky Medication Adherence Scale (MMAS, Table 1) was initially used to measure 76 
adherence to medications in subjects with hypertension [13].  The advantages of the scale 77 
are that it is easy to administer, simple and consists of non-judgemental, non-threatening 78 
questions [14].  Some studies, have disputed the effectiveness of the MMAS-4, finding that it 79 
considerably overestimates adherence [15]. Furthermore, it has been observed that subjects 80 
have a strong affinity towards selecting answers that indicated good adherence to medicine 81 
[16,17]. Thus, the Morisky scale may not be the ideal way to measure adherence.   82 
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The most common way of quantifying adherence to medicines is by using the Medicines 83 
Possession Ratio (MPR), which is the total number of days covered by the prescription 84 
divided by the days in the same time period.  The major advantage of the MPR is that it is a 85 
quantitative measure, and it not biased by self-reporting.  The major limitation to using MPR, 86 
as a measure of adherence, is that it measures prescriptions collected, not the use of 87 
medicines [18].  The final results section considers a study that used both the Morisky scale 88 
and MPR to measure adherence to anti-diabetes drugs. 89 
Methods 90 
A literature search of Medline and CINAHL from their start until November, 2013 and of the 91 
first 400 search items from Internet (Google) was undertaken.  The search terms were 92 
‘diabetes’ with ‘adherence’ (or compliance, concordance, persistence, continuation) with 93 
‘HbA1c’ (or glycaemic control), and there were no exclusions at this stage.  The database 94 
searching of Medline produced 792 records.  Searching of CINAHL and the first 400 search 95 
items from Google did not produce additional items.  Search results not relevant to the 96 
adherence to medicines were excluded i.e. adherence to protocols or lifestyle changes.  97 
Non-English abstracts were then also excluded, and both authors independently read the 98 
English abstracts only.  The authors download/obtained all papers which seemed to address 99 
the association of adherence to medicines and HbA1c, and relevant studies that had been 100 
referenced in the retrieved studies were also downloaded or obtained via interlibrary loan.  101 
Thus, no papers were excluded from the review on the basis of design of study or quality. 102 
Results 103 
A flow diagram of the literature search for relationship between adherence to anti-diabetes 104 
medicines and HbA1c is given in Figure 1.  In total, 730 of 792 abstracts were excluded, and 105 
62 full papers were collected.  Further analysis of the 62 papers showed that only 23 papers 106 
were directly relevant to the review and these were all included.   Of the 23 studies, 10 107 
studies used qualitative and 12 using quantitative methods to measure adherence to anti-108 
diabetes medicines, and one study using both qualitative and quantitative methods.  Five of 109 
the qualitative studies used non-Morisky measurements and 5 used the Morisky score. 110 
Qualitative, non-Morisky measurements of adherence and association with HbA1c 111 
levels 112 
Using qualitative, non-Morisky measurement of adherence to medicines, four (Table 2) of 113 
five studies have shown an association with HbA1c levels.  Thus, in these four studies an 114 
association between adherence and glycaemic control was shown to exist, despite the 115 
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qualitative measurement and each study having the limitation that subjects were recruited 116 
from a single source (Table 2).   117 
The one study that did not show an association was a smaller US study, which enrolled 77 118 
subjects with type 2 diabetes, mean age 52 years, and a HbA1c > 9% [10].  At baseline, 119 
these subjects had an HbA1c of 10.4%, and most (65%) were using two or more oral anti-120 
diabetes medicines, and 55% were using insulin [10].  Adherence was assessed by asking 121 
(1) ‘Taking medication on a regular basis can be difficult. Do you ever find it difficult to take 122 
(insert medication name)?’ If yes, then (2) ‘How many times over the last two weeks have 123 
you missed a dose?’ [10]. Twenty-four per cent of subjects were not taking medicine as 124 
prescribed [10].  Bivariate linear regression did not show an association between adherence 125 
and HbA1c (P = 0.37) [10].  A limitation to this study is the small sample size [10].  Another 126 
limitation to this study is that it only included subjects with an HbA1c > 9%, and thus there 127 
are no HbA1c levels ≤ 9% to provide a range of HbA1c levels that included levels lower than  128 
9% in their regression analysis between adherence and HbA1c. 129 
Morisky scale measurements of adherence and association with HbA1c levels 130 
Five studies that have used the Morisky scale to measure adherence to anti-diabetes 131 
medicines, and four have shown an association with HbA1c (Table 3).  132 
One of the five studies did not show a relationship between Morisky score and adherence to 133 
medicines.  This study was conducted in 125 subjects with type 2 diabetes and a mean 134 
HbA1c of 7.6%; 71.4% were African-Americans, about half were < 65 years old, and 64.2% 135 
had an income of ≤ US15,000 [11].  In this study, multiple linear regression did not show a 136 
relationship between HbA1c and Morisky score (-0.11: 95% CI; -0.56, 0.35) [11].   137 
Medicine possession ratio (MPR) measurements of adherence and association with 138 
HbA1c levels 139 
Of the ten studies using MPR, nine studies have suggested that there is an association 140 
between adherence to medicines in subjects with type 2 diabetes and HbA1c levels.  All of 141 
the studies showing an association were performed in USA and the results are summarised 142 
in Table 4.    143 
In contrast to the US studies using MPR (Table 4), a Swedish study measuring adherence to 144 
oral hypoglycaemic agents did not find a clear cut relationship with HbA1c [9].  This study 145 
enrolled 346 subjects with type 2 diabetes, mean age ~64 years, and mean HbA1c of 6.5%, 146 
who were taking oral anti-diabetes medicines and/or insulin [9].  Subjects with MPR ≥ 80% 147 
were considered to be adherent [9].  Seventy-four percent of subjects taking oral anti-148 
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diabetes medicines were adherent with a HbA1c of 6.5%, compared to 6.8% for the 149 
nonadherent (P = 0.025) [9].  However, when the adherence to oral anti-diabetic agent/no 150 
insulin and insulin/no oral anti-diabetic agent was separated, only adherence to insulin/no 151 
oral anti-diabetic agent was associated with HbA1c (6.6% vs 7.3% for nonadherence) [9].  152 
According to the authors, a factor that may have contributed to this is that overall adherence 153 
was greater to oral anti-diabetic medicines (84%) than to insulin (69%)  [9].  A major 154 
difference between this and the other studies, which have shown a clear cut association 155 
between adherence and HbA1c, is that the baseline HbA1c levels in this study were much 156 
lower than in the studies listed in Table 4, and thus this is a much better controlled group of 157 
subjects with diabetes than in the other studies. 158 
MPR measurements of adherence to insulin only and association with HbA1c levels 159 
Quantitative measures of adherence in the Diabetes Audit and Research in Tayside, 160 
Scotland (DARTS/Medicines Monitoring Unit (MEMO)) study have shown a relationship 161 
between adherence to insulin and HbA1c levels.  Adherence was measured as the annual 162 
number of days of insulin coverage, calculated from the amount of drug dispensed at 163 
community pharmacies and recommended dose level for each subject, and nonadherence 164 
was < 80% [36,37].  The initial study was of 89 adolescents with type 1 diabetes and a mean 165 
age of 16 years, and univariate analysis showed a significant inverse association between 166 
adherence and HbA1c levels, which remain after adjustments for all other covariates (R2 = 167 
0.39,  P = 0.001) [36].  168 
In the study with adults, there were 1099 subjects with type 2 diabetes, with a mean age 62 169 
years, who were treated with insulin, and had a mean HbA1c of 8.5% [37].  Using mixed-170 
effects linear regression, there was a significant inverse association between log adherence 171 
to insulin and HbA1c levels (estimate = 1.22, P < 0.0001) [37].  The association between 172 
insulin use and HbA1c levels has also been demonstrated by ordinary least-squares 173 
regression in 6222 subjects with type 2 diabetes (estimate = -0.0045), where adherence was 174 
measured by dividing the sum of total days’ supply of insulin, by the sum of the total days in 175 
the treatment period [38].  In the adult studies of adherence to insulin, the subjects with type 176 
2 diabetes were also taking oral anti-diabetes agents [37,38], but the adherence to these 177 
agents was not measured. 178 
Qualitative and quantitative measurement of adherence and association with HbA1c 179 
levels in a single study 180 
A 2010 study enrolled  526 black (62%), Hispanic (23%) or white/other low income subjects 181 
with type 2 diabetes, with a mean age of 56 years and HbA1c of ≥ 7.5% (mean, 8.6%) [12].  182 
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The study used two qualitative measures of adherence to oral glucose lowering medicines 183 
(the 4-item Morisky scale, and medication-taking items of the Summary of Diabetes Self-184 
Care Activities, SDSCA) and a quantitative measure (claims data medicines possession 185 
ratio, MPR) [12].  There was a strong Spearman correlation between the MPR and the 186 
Morisky scale and the SDSCA medication adherence item (both p = 0.21, P <0.001), but 187 
there was no correlation between MPR, Morisky or SDSCA and HbA1c levels [12].  The 188 
authors pointed out that the enrolment criteria of an HbA1c of ≥ 7.5% is a limitation in this 189 
study [12].   190 
Discussion and Conclusion 191 
This is the first review to show that irrespective of measurement type, adherence is usually 192 
associated with HbA1c levels in subjects with diabetes.  Thus, using qualitative, non-Morisky 193 
or Morisky measurements of adherence to anti-diabetes medicines, eight of ten studies have 194 
shown an association with HbA1c levels.  Nine of 10 studies using the MPR, and two studies 195 
using MPR for insulin only, have also shown an association between adherence to anti-196 
diabetes medicines and HbA1c levels.  The one study that used both Morisky and MPR did 197 
not show an association.   198 
The question posed by this review was: Does an association between adherence to anti-199 
diabetes medicines and HbA1c depend on how we measure adherence?  It seems that there 200 
may be an association between adherence to anti-diabetes medicines and HbA1c levels. 201 
and this is not dependent on how we measure adherence.  Thus, regardless of whether 202 
adherence is measured qualitatively or by MPR, the majority of studies show the association 203 
(Tables 2, 3, and 4).  Thus, the limitations to these ways of measuring adherence (discussed 204 
in the introduction) are not a factor in the association.   205 
However, there are two situations in which the association is not apparent.  The first is when 206 
a range of HbA1c values (low to high values) are not used to determine whether there is an 207 
association, and this was the case for 3 of the 4 studies that did not show association 208 
[9,10,11].  Thus, we recommend that future studies of the relationship between adherence to 209 
medicines and HbA1c levels, ensure that they have a range of values of HbA1c. 210 
The second situation when an association between adherence to anti-diabetes medicines 211 
and HbA1c levels was not always apparent was when a low income population was 212 
investigated [11,12].  One of these studies [12] also did not have a range of HbA1c values, 213 
which may have contributed to the lack of an association.  This absence in association 214 
between adherence to medicines use and HbA1c levels observed in two studies [11,12] may 215 
also be indirectly attributed to high medicine cost.  Thus, two large studies, which used 216 
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qualitative, non-Morisky measurements of adherence, have shown a relationship between 217 
cost-related adherence and HbA1c levels [39,40].  The first of these studies included 766 218 
adults with diabetes and 17.7% reported cost-related medication underuse, [39]. Subjects 219 
who had ‘cost-related’ nonadherence of medication had higher HbA1c values (8.7%) than 220 
those who were adherent (7.9%) [39].  The second study of cost-related nonadherence 221 
showed that it is was higher among Mexican Americans (53%) than Vietnamese Americans 222 
(28%) or white subjects (27%), and was independently associated with HbA1c [40].  Another 223 
possible reason for lack of association in the low income populations, of adherence to anti-224 
diabetes medicines and HbA1c levels is race/ethnicity; African-Americans and/or Hispanics 225 
[11,12].  Thus, low income populations of these groups, have poorer glycaemic control than 226 
whites with low incomes [14].  This may have contributed to the lack of association.  Further 227 
studies are required to clarify the relationship between race/ethnicity and income in these 228 
groups to HbA1c levels. 229 
Limitations to this review include that it is not a systematic review, and that only some 230 
databases were searched.  Most of studies have been undertaken in the US, and thus it is 231 
not clear whether the findings of the review are universal. 232 
In conclusion, most studies show an association between adherence to anti-diabetes 233 
medicines and HbA1c levels, and this seems to be independent of method used to measure 234 
adherence.  However, to show an association it is necessary to have a range of HbA1c 235 
values.  Also, the association is not always apparent in low income populations.  236 
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Figure 1: Flow diagram of literature search for relationship between adherence to anti-diabetes medicines and HbA1c 373 
  374 English abstracts identified from 
Medline 
(n = 792) 
  
Additional records identified from CINAHL 
and Internet (Google: first 20 pages)  
(n = 0) 
  
Abstracts screened   
(n = 792) 
  
Abstracts excluded   
(n = 730) 
  
Full articles assessed for eligibility 
(n = 62) 
  
Full-text articles 
excluded (n = 40) 
  
Studies included in review 
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Table 1 Morisky Medication Adherence Scale (MMAS) 375 
1. Do you ever forget to take your medicine? 376 
2. Are you careless at times about taking your medicine? 377 
3. When you feel better do you sometimes stop taking your medicine? 378 
4. Sometimes if you feel worse when you take the medicine, do you stop taking it? 379 
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Table 2 Studies showing an association between the non-Morisky qualitative measurement of adherence and HbA1c in subjects with type 2 380 
diabetes  381 
Reference 
 
Country Population Baseline 
HbA1c  
Sample 
Size 
Adherence 
to  
Methods, findings/associations Limitations 
Kadmon & 
Gruppuso, 
2004 [19] 
US Adolescents; white 
56%, Hispanic 
22%, Black 17%; 
body mass index 
(BMI) of 34 kg/m2 
 18 Metformin Self-reported adherence was reported as good or 
poor/fair. Those with good adherence had a HbA1c of 
about 7% and with poor/fair about 11% (P < 0.005).  
Preliminary, retrospective, 
small study using data up 
to 2000 in subjects 
attending hospital. 
Rhee et al, 
2005 [20]   
US Average age of 55 
years, 90% African 
American, 63% 
were female, BMI 
was 32 kg/m2, 
duration of 
diabetes was 4.6 
years, 
9.1% 1263 Anti-
diabetes 
medicines; 
Insulin use 
by 40%.   
Adherence measured by self-report, compared to 
recommended use.  Baseline, adherence was high, 76-
100%.  In multivariable linear regression analysis, after 
controlling for other factors, greater adherence in taking 
recommended diabetes medications was a significant 
predictor of subsequent HbA1c levels (P = 0.0009, β 
coefficient = -0.346).    
 
Retrospective evaluation, 
using data up to 2001.  
Assessment was only in 
those that kept their 
appointments at a 
diabetes clinic. 
Heisler et 
al, 2007 
[21].   
US ≥ 55 years  HbA1c was 
higher in 
Black 
(8.1%) and 
Latino 
respondents 
(8.1%) than 
the White 
respondents 
(7.2%) 
1034 Oral anti-
diabetes 
medicines 
and insulin 
Subjects were asked how often in a typical week they 
missed a prescribed dose of their oral diabetes 
medications and, if receiving insulin, how often they 
missed a scheduled insulin dose, and from the 
responses, subjects were divided into 5 categories from 
‘never’ to ‘very often’.  Adherence to medication was 
higher in the White (66%) and Latino (66%) than the 
Black population (55%).  In multivariate linear 
regression analyses, an independent association 
between adherence and HbA1c was shown (P < 0.05, 
β coefficient = 0.43).   
Part of the Health and 
Retirement Study, which 
over samples black and 
Latino subjects.  Only 
1034 of a possible 2350 
subjects with diabetes 
responded. The 
respondents were more 
likely to have higher 
incomes and more 
education, and to be 
white.   
Mashitana 
et al, 2013 
[22] 
Japan Mean age 65 
years, BMI was 
24.7 kg/m2   
7.8% 1441 Insulin Subjects were asked how often they had missed an 
insulin injection in the last month, and on the basis of 
the answers were classified as higher (never), middle 
(seldom) and lower (less of than half of the time.  
Higher adherence was associated with better glycaemic 
control (HbA1c < 7.0).  RRs were 1, 0.76 and 0.53 for 
higher, middle and lower adherence, respectively (P = 
0.003). 
Performed in a diabetes 
speciality centre and may 
not apply to other 
populations. 
 382 
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Table 3 Studies showing an association between the Morisky scale and HbA1c in subjects with type 2 diabetes 
Reference Country Population Baseline 
HbA1c 
Sample 
Size 
Adherence 
to 
Methodological refinements and 
findings/associations  
Limitations 
Krapek et 
al, 2004 
[23] 
US White (47%), 
black (37%), 
Hispanic (13%); 
56% were 
obese or 
morbidly obese 
Range 5-
13% 
301 Anti-diabetes 
medicines; 
34% were 
using insulin 
For Morisky scores of 0 or 1, 2, 3, and 4, the HbA1c 
scores were 8.92%, 8.67%, 7.74%, and 7.60%, 
respectively.  In multiplicative regression, the 
Morisky score was significantly correlated with 
HbA1c (P < 0.001).   
Six hospital practice sites 
from a Diabetes Goals 
Project; practice site was a 
significant variable.  
Hill-Briggs 
et al, 2005 
[24]   
US Urban African 
Americans; 89% 
living in poverty 
8.6% 172 Anti-diabetes 
medicines; 
53% were 
using insulin 
A modified Morisky scale with a fifth question 
asking “Do you ever run out of your medicine”. 
Subjects with a score of 5 were considered 
adherent to the diabetes medicines and those with 
0-4 nonadherent; adherence was 74%.  HbA1c was 
lower for adherent subjects (8.4%) than 
nonadherent subjects (10.6%) by t-test, P = 0.005.   
As part of Project Sugar 1, 
participants were recruited 
from two Johns Hopkins-
affiliated primary care 
clinics.  Self-selection of 
population; 481 eligible 
subjects did not participate. 
Al-Qazaz et 
al, 2011 
[25]   
Malaysia 39% Chinese, 
34% Malay and 
27% Indian.  
505 subjects 
with a mean 
age of 58 years,  
7.6% 505 Anti-diabetes 
medicines; 
22% were 
using insulin.   
Eight point rather than 4 point Morisky score.  
Multivariate binary logistic regression analysis and 
adjusted odds ratios showed the HbA1c levels were 
correlated with Morisky score (OR = 2.01, P < 
0.001).   
Participants were from one 
hospital diabetes clinic, but 
good representation 
(93.5%). 
Wang et al, 
2012 [26]   
Singapore Predominantly 
Chinese 
(75.9%),  
8.0% 294 Anti-diabetes 
medicine; 29% 
were using 
insulin 
Ceiling effect on the Morisky score at 3 of 35.7% 
and only 29.6% of respondents answering 4, the 
highest adherence. Subjects with higher scores on 
the Morisky scale had low HbA1c levels (P < 
0.001). 
 
Cross-sectional, 
convenience sample from 
subjects attending National 
Healthcare Group 
Polyclinics (primary-care), 
but good response rate 
(81.4%).   
Aikens & 
Piette, 2013 
[27] 
US Predominantly 
African-
American 
ethnicity (57%), 
with a mean 
age of 56 years  
59% had 
HbA1c > 
7.0% 
287 Anti-diabetes 
medicines; 
40% were 
taking insulin. 
51% had high adherence, 42% medium, and 7% 
low adherence on the Morisky scale at baseline.  
Using multiple regression analysis, adherence to 
medicines was associated with baseline HbA1c (β = 
0.25, P = 0.001).   
Of 420 telephoned in a 
large Midwestern urban 
healthcare system, 287 
subjects consented. 
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Table 4 Studies showing an association between Medicine Possession Ratio (MPR) and HbA1c in subjects with type 2 diabetes 
Reference Population Baseline 
HbA1c 
Sample Size Adherence 
to  
Methodological refinements and 
findings/associations 
Limitations  
Schectman 
et al, 2002 
[28] 
Low income, 
African-Americans 
(42%), Caucasians 
(58%), mean age 
59 years  
8.1% 810 Oral anti-
diabetes 
medicines; 
Adherence to 
insulin was 
not 
measured. 
30% had concomitant insulin.  Adherence to oral anti-diabetic 
drugs gave MPR = 79.7%.   Adherence greater in Caucasians 
(82%) than African-Americans (76.5%).  Bivariable analysis 
showed strong association between adherence and HbA1c 
(Parameter estimate = -0.019, P < 0.001, R2 = 4.0%). In 
multivariable analysis, the independent association of 
adherence and HbA1c was still apparent (-0.016, P < 0.0001, 
R2 = 2.7%). 
University primary care practice 
site; 61% living in Federal poverty. 
Pladevall et 
al, 2004 
[29] 
African-Americans 
(41%), Caucasians 
(53%), mean age 
64 years 
8.0% 677 46% of 
subjects 
taking 
metformin 
Subjects using insulin were excluded.  Adherence to metformin 
was associated with HbA1c; r = 0.25, P < 0.01.  
Study was limited to insured 
subjects with prescription drug 
coverage enrolled in a health 
maintenance organisation. Study 
was limited to one anti-diabetes 
medicine. 
Ho et al, 
2006 [7] 
Mean age 64 
years  
 11,532 Oral anti-
diabetes 
medicines 
25% of subjects taking oral anti-diabetic drugs were also 
taking insulin, but this was not measured. Nonadherence was 
considered to be < 80% adherent, and 2456 subjects were 
nonadherent with HbA1c of 8.1%, compared to 7.7% in the 
adherent subjects; t-test, P < 0.001. 
Retrospective, but with large 
population from managed care 
organisation.  Main objective was 
to determine clinical outcomes. 
Lawrence 
et al, 2006 
[30] 
Mean age ~52 
years  
mean HbA1c 
~ 7.8%, 
Sulfonylurea 
= 655 
Metformin = 
1013 
Both = 402 
Sulfonylureas 
and 
metformin 
separately 
and together 
About 20% of subjects were using insulin, but this was not 
considered. For sulfonylureas, the mean adherence of 77%, 
and for this group a Pearson correlation analysis showed an 
inverse association between MPR and HbA1c (r = -0.295, P 
<0.001). For metformin, there was a lower adherence (70%), 
and an inverse association between MPR and HbA1c (r = -
0.285, P <0.001).  There was also a correlation between 
adherence to both a sulfonylurea and metformin with an 
inverse association between HbA1c and MPR (r = 0.65, P 
<0.001).   
Retrospective subjects in diabetes 
management programme but 
without medication adherence 
counselling.  Medicines considered 
separately.   
Rozenfeld 
et al, 2008 
[31] 
Subjects had not 
previously 
received 
medicines for 
diabetes, mean 
age 54 years  
8.0% 249 Oral anti-
diabetes 
medicines 
Although the mean adherence to oral diabetes medicines was 
81%, only 65% of subjects had adherence > 80%. Multiple 
regression established as association between HbA1c and 
percentage adherence.   
Retrospective observational study 
in primary care organization with 
health insurance.  Findings only 
relate to subjects who are newly 
treated.  
Adams et 
al, 2008 
[32] 
Newly diagnosed 
with type 2 
diabetes, none of 
Baseline 
HbA1c levels 
were higher in 
467 black and 
1339 white 
subjects, 
Oral anti-
diabetes 
medicines 
Adherence at 12 months was 72% and 78% for black and 
white subjects, respectively, P < 0.0001.  More frequent 
medication refills were associated with lower average HbA1c 
Retrospective, cohort study.  
Subjects were from University clinic 
sites and had health insurance. 
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whom were taking 
insulin  
the black than 
white subjects 
(9.8% vs 
8.9%).   
values, and increases in adherence were associated with 
lower HbA1c values.  
Findings only relate to subjects 
who are newly treated. 
Horswell et 
al 2008 [33] 
Study that 
supplied free 
medication, for an 
uninsured, low 
income population 
(78% African 
American, mean 
age 52 years  
8.73% 289 Oral anti-
diabetes 
medicines 
Mean HbA1c was reduced by 0.19, 0.69 and 0.88% with one, 
two and three refills, respectively. 
Retrospective longitudinal data. 
Low income population from 
healthcare division that supports 
the indigent and uninsured.  
Kim et al, 
2010 [34] 
Study of newly 
medicated Veteran 
Administration 
subjects, 67% 
were white, 97% 
were male, mean 
age 63 years  
7.7% 56,181 Oral anti-
diabetes 
medicines 
and insulin 
(4% using) 
Measured over a year, 52% had good adherence (80-110%) 
whereas 23% were nonadherent (<80%), and the others were 
overadherent.  Good adherence was independently associated 
with a goal HbA1c of ≤ 7.0%, when compared with 
nonadherence (RR = 1.06).    
Findings only relate to newly 
medicated Veteran Administration 
subjects. 
Zhu et al, 
2011 [35] 
compared 
adherence to oral 
hypoglycemic 
agents in 834 
African Americans 
to 3142 white 
subjects, mean 
age was about 50 
years  
HbA1c levels 
of African 
American and 
white subjects 
was 7.4% and 
6.9%, 
respectively 
3,976 Oral anti-
diabetes 
medicines 
Adherence was 40% and 50% for African American and white 
subjects, respectively.  With adherence being a MPR of ≥ 
80%, and nonadherence, 80%, using linear regression models 
adherence was significantly inversely correlated with HbA1c 
levels for both African-Americans (P < 0.0001) and whites (P < 
0.0001). 
Excluded subjects that used 
insulin.  Only subjects with HbA1c 
levels at the state health 
information exchange were 
enrolled. 
 
